MDSpire - Takeaway
Commentary & Perspectives

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

Share

  • 1

    Dr. Ebert is a fourth-generation physician.

  • 2

    He became President and CEO of Dana-Farber Cancer Institute on October 1,

  • 3

    His research focuses on blood disorders and cancers.

  • 4

    Ebert has received the Sjöberg Prize for his work in hematology.

  • 5

    He emphasizes AI's role in improving cancer drug development.

  • 6

    His career reflects a legacy of mentorship in medicine.

  • 7

    Ebert's family has a strong tradition in the medical field.

Original Source(s)

In Celebration of a Decades-Long Journey of Discovery and Innovation

  • by Jo Cavallo

  • March 24, 2026

Related Content

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...